## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.9% in mid entry zone (4.0-10.0%), top 7% cross-sectional ranking. Short-term MRS_5 (1.2%) confirms momentum alignment. Outperforming sector by 13.4%. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($17.53)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Russell Investments Group Ltd. Has $5.06 Million Stock Holdings in CareDx, Inc. $CDNA**
- Source: MarketBeat | 20251207T034428 | Neutral | Relevance: 100%
-  Russell Investments Group Ltd. significantly reduced its stake in CareDx, Inc. (NASDAQ:CDNA) by 56.5% during the second quarter, selling 335,982 shares and retaining 258,869 shares valued at approximately $5.06 million. Despite this reduction from one institution, other hedge funds adjusted their holdings, with some increasing their positions in CareDx. CareDx recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.28 and revenue of $100.06 million, alongside robust profitability metrics.

**2. CareDx, Inc. $CDNA Shares Bought by Hood River Capital Management LLC**
- Source: MarketBeat | 20251208T121002 | Somewhat-Bullish | Relevance: 97%
-  Hood River Capital Management LLC increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 11.5% in the second quarter, now owning 1,765,981 shares valued at approximately $34.5 million. CareDx reported strong quarterly results, surpassing EPS and revenue estimates, and analysts currently rate the stock as a "Hold" with a consensus target price of $26.00. The company engages in the development and commercialization of diagnostic solutions for transplant patients.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($0.23M) |
| Sells | 6 ($0.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.9%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 22.0x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.0B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.0 |
| Current P/E | 28.0 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 10.8% to 8.9% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 11.2% shows strong absolute momentum above own 20MA. Outperforming sector by 13.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.92% (CS: 93) | Strong |
| RSI_14 | 65.9 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.112x | Above |
| vs SMA50 | 1.214x | Above |
| vs SMA200 | 1.175x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $19.25
- **Stop Loss:** $17.53 (8.9% risk)
- **Target:** $21.83 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 174
- **Position Value:** $3,349.50
- **Portfolio %:** 3.35%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*